HighTower Advisors’s BioAtla BCAB Stock Holding History

HighTower Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-260	Closed	-$7.38K	–	3811
2025 Q4	$7.38K	Hold	260	–	–	﹤0.01%	3641
2025 Q3	$8.94K	Hold	260	–	–	﹤0.01%	3701
2025 Q2	$5.15K	Hold	260	–	–	﹤0.01%	3675
2025 Q1	$4.51K	Hold	260	–	–	﹤0.01%	3589
2024 Q4	$7.69K	Hold	260	–	–	﹤0.01%	3599
2024 Q3	$23K	Sell	260 -10	-4%	-$839	﹤0.01%	3499
2024 Q2	$19K	Buy	270 +10	+4%	+$1.19K	﹤0.01%	3402
2024 Q1	$45K	Sell	260 -8	-3%	-$994	﹤0.01%	3265
2023 Q4	$33K	Buy	268 +8	+3%	+$694	﹤0.01%	3354
2023 Q3	$22K	Hold	260	–	–	﹤0.01%	3321
2023 Q2	$39K	Hold	260	–	–	﹤0.01%	3187
2023 Q1	$35K	Hold	260	–	–	﹤0.01%	3086
2022 Q4	$107K	Hold	260	–	–	﹤0.01%	2933
2022 Q3	$100K	Hold	260	–	–	﹤0.01%	2767
2022 Q2	$37K	Buy	+260	New	+$41.4K	﹤0.01%	2942

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HighTower Advisors's BCAB Position: Q1 2026 in Review

HighTower Advisors sold out of BioAtla (BCAB) in Q1 2026, closing a stake of 260 shares — an estimated $7.38K sold.

HighTower Advisors first reported a position in BCAB in Q2 2022 and held it in 15 quarters. The position peaked at $107K in Q4 2022. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

HighTower Advisors reported no remaining BioAtla position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 260 BioAtla shares in Q1 2026, an estimated $7.38K.
HighTower Advisors first reported a position in BioAtla in Q2 2022 and held it in 15 quarters.
HighTower Advisors's BioAtla position peaked at $107K in Q4 2022.
36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.